IMDX

$0.00

(

0.00%

)
Quote details

stock

Insight Molecular Diagnostics Inc.

NASDAQ | IMDX

2.85

USD

0.00

(

0.00%

)

AT CLOSE (AS OF Jul 3, 2025)

-

MARKET CAP

-

P/E Ratio

-

EPS

$4.8

52 Week High

$1.9

52 Week Low

LIFE SCIENCES

Sector

IMDX Chart

Recent Chart
Price Action
1D
Candles

Trade Smarter

Automate your trading workflow with powerful tools — built for serious traders.

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback's Trading Journal

IMDX Technicals

Tags:

IMDX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $740K
Total Revenue $1.9M
Cost Of Revenue $1.1M
Costof Goods And Services Sold $1.1M
Operating Income -$61M
Selling General And Administrative $10M
Research And Development $9.8M
Operating Expenses $61M
Investment Income Net -
Net Interest Income -$84K
Interest Income -
Interest Expense $84K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.6M
Income Before Tax -$61M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$61M
Comprehensive Income Net Of Tax -
Ebit -$61M
Ebitda -$59M
Net Income -$61M

Revenue & Profitability

Earnings Performance

IMDX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $35M
Total Current Assets $12M
Cash And Cash Equivalents At Carrying Value $8.6M
Cash And Short Term Investments $8.6M
Inventory $410K
Current Net Receivables $1.6M
Total Non Current Assets $23M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $15M
Intangible Assets Excluding Goodwill $15M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.1M
Other Non Current Assets -
Total Liabilities $47M
Total Current Liabilities $7.3M
Current Accounts Payable $2.3M
Deferred Revenue -
Current Debt -
Short Term Debt $1.3M
Total Non Current Liabilities $40M
Capital Lease Obligations $3.7M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.7M
Other Current Liabilities $3.7M
Other Non Current Liabilities $38M
Total Shareholder Equity -$12M
Treasury Stock -
Retained Earnings -$351M
Common Stock $338M
Common Stock Shares Outstanding $13M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$21M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.6M
Capital Expenditures $516K
Change In Receivables -
Change In Inventory -$410K
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $20M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$5.4M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$61M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $740K
Total Revenue $1.9M
Cost Of Revenue $1.1M
Costof Goods And Services Sold $1.1M
Operating Income -$61M
Selling General And Administrative $10M
Research And Development $9.8M
Operating Expenses $61M
Investment Income Net -
Net Interest Income -$84K
Interest Income -
Interest Expense $84K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.6M
Income Before Tax -$61M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$61M
Comprehensive Income Net Of Tax -
Ebit -$61M
Ebitda -$59M
Net Income -$61M

IMDX News

IMDX Profile

Insight Molecular Diagnostics Inc. Profile

Sector: LIFE SCIENCES

Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.

Discover more tools and features to empower your trading
Explore Features

Quotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.